AFFiRiS Announces Encouraging Long-term Data from a Series of First-in-Human Studies Using AFFITOPE® PD01A Targeting Oligomeric Alpha-synuclein in Early Parkinsons Disease Patients

•Reevaluation of primary and secondary endpoints confirms safety and tolerability and immunogenicity profile of long-term application over 4 years of AFFITOPE® PD01A

•Prof. Werner Poewe, Chairman of the Department of Neurology at the Medical University Innsbruck, Austria, and Leading PD Expert, Presented Results at a Late Breaking Symposium on Treatment Strategies in PD at the AAT-ADPD Focus Meeting in Turino, Italy on March 17